Background: In 2017, a South Australia Perinatal Practice Guideline was introduced state-wide for the use of subcutaneous fentanyl for labour analgesia as a replacement for intramuscular pethidine. We retrospectively reviewed the implementation of this practice change in our institution.
Methods: A retrospective review of maternal and neonatal case notes for the first 100 women administered subcutaneous fentanyl in labour at a single tertiary referral centre for maternity care, between February and June 2017.
Results: Of the 102 women administered subcutaneous fentanyl, the majority (55%) were primipara, with an average maternal age of 29 years and body mass index of 27 kg/m. The median total fentanyl dose administered was 200 µg and the average time from last dose to birth was 3 h. The majority of women (70%) did not require additional rescue labour analgesia and 80% had a spontaneous vaginal birth. All neonates had a 5-min Apgar score >7. The median Apgar score at 1 and 5 min was 9. No neonate had an arterial cord blood pH <7.1. The mean arterial and venous cord blood pH was 7.3. The average time for neonates to establish breathing was 1 min and the median postnatal length of stay was two days.
Conclusions: Subcutaneous fentanyl for labour analgesia appears effective and has a low incidence of adverse events.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijoa.2020.10.009 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Development and preclinical testing of a naloxone prodrug depot for extended protection against opioid overdose.
Nat Commun
January 2025
Department of Pharmaceutical Sciences, Thomas J. Long School of Pharmacy, University of the Pacific, Stockton, CA, US.
The opioid crisis, driven by synthetic opioids like fentanyl, demands innovative solutions. The opioid antidote naloxone has a short action ( ~ 1 hour), requiring repeated doses. To address this, we present a new and simple naloxone prodrug delivery system repurposing a hydrophilic derivative of acoramidis, a potent transthyretin ligand.
View Article and Find Full Text PDFDirect Induction of Buprenorphine Extended-Release: A Case Report.
J Addict Med
December 2024
From the Integrated Psychiatry, Pain, and Addiction Service, Vancouver General Hospital, Vancouver, British Columbia, Canada (PA, JSHW, JM, MN, VWL, MJI, NM); Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada (PA, MN, VWL, MJI, NM); Addictions and Concurrent Disorders Research Group, Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada (JSHW, RMK); Substance Use Response and Facilitation Service, BC Children's Hospital, Provincial Health Services Authority, Vancouver, British Columbia, Canada (MJI); BC Mental Health & Substance Use Services, Provincial Health Services Authority, Vancouver, British Columbia, Canada (NM); Bridge, Public Health Institute, Oakland, CA (AAH); Department of Emergency Medicine, Highland General Hospital-Alameda Health System, Oakland, CA (AAH); Department of Emergency Medicine, University of California, San Francisco, CA (AAH); The C4 Foundation, Coronado, CA (RM); British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada (JSGM); Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada (JSGM); and Pharmacokinetics Modeling and Simulation Laboratory, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada (ARM).
Buprenorphine has superior safety in opioid use disorder compared with alternatives due to its action as a partial opioid agonist, which limits its ability to cause respiratory depression. There is a risk of precipitated opioid withdrawal after buprenorphine exposure in someone using full opioid agonists. Buprenorphine induction strategies that avoid precipitated withdrawal remain a crucial component for starting buprenorphine in individuals actively using opioids.
View Article and Find Full Text PDFThe Effect of Lidocaine Splash Block Followed by Suspensory Ligament Massage in Female Dogs Undergoing Ovariohysterectomy: A Prospective Study.
Animals (Basel)
December 2024
Surgery Clinic, Faculty of Veterinary Medicine, University of Thessaly, 43100 Karditsa, Greece.
The administration of lidocaine as part of multimodal analgesia in dogs undergoing ovariohysterectomies demonstrates variable analgesic efficacy. The aim of this prospective, double-blinded clinical study was to evaluate the effectiveness of lidocaine 2% irrigation on the ovarian suspensory ligament, followed by localised massage, in achieving sufficient intraoperative analgesia. Thirty-eight female dogs were randomly divided to two groups and received either a splash block of 0.
View Article and Find Full Text PDFExploring Opioid Use Disorder Outcomes by Quantitative Urinalysis: Post Hoc Analysis of a Phase 3 Randomized Clinical Trial.
J Addict Med
December 2024
From Camurus AB, Lund, Sweden (SP, FT); New York State Psychiatric Institute, Columbia University Irving Medical Center, New York, NY (EVN); and Center on Drug and Alcohol Research, University of Kentucky College of Medicine, Lexington, KY (MRL, SLW).
Article Synopsis
- Opioid use disorder (OUD) is a pressing global issue, and while urine drug screenings help monitor treatment responses, they typically provide only yes/no results, complicating comparisons between studies due to varying analytical cutoffs.
- This study analyzed data from a 31-week trial involving 428 participants to compare the efficacy of CAM2038 (subcutaneous buprenorphine) to daily sublingual buprenorphine/naloxone, using quantitative urine drug tests to evaluate different cutoffs for opioid detection.
- Results showed that higher cutoff values led to more pronounced differences in treatment effectiveness favoring CAM2038, suggesting that quantitative urinalysis can offer
Examining the Severity and Progression of Illicitly Manufactured Fentanyl Withdrawal: A Quasi-Experimental Comparison.
J Addict Med
November 2024
From the Johns Hopkins School of Medicine, Behavioral Pharmacology Research Unit, Baltimore, MD (AS, KED, KS-D, SD, NK, ECS, CB); and Friends Research Institute Baltimore, MD, (AS).
Objective: Illicitly manufactured fentanyl has largely replaced heroin throughout the United States. Characteristics of fentanyl-specific withdrawal are not well understood compared to traditional opioid withdrawal. This study examines opioid withdrawal severity among 2 cohorts of study participants who underwent identical morphine stabilization procedures before and after fentanyl was introduced to the local drug market.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!